Treatment changes of coronavirus infection disease (SARS-COV-2). What general practitioner should know? Part 1

Abstract

The article presents an overview of methods of treatment of coronavirus infection based on available data from recent clinical studies and methodological recommendations. Drugs recommended as etiotropic therapy are considered. Data from clinical trials and expert opinions are analyzed.

Keywords

coronavirus infection / etiotropic therapy / COVID-19 / SARS-CoV-2

References

[1] Федеральный закон «Об основах охраны здоровья граждан в Российской Федерации» от 21.11.2011 № 323-ФЗ (последняя редакция). [Federal Law of Russian Federation No. 323-FZ “Ob osnovakh okhrany zdorov’ya grazhdan v Rossiyskoy Federatsii“, dated 21.11.2011. (In Russ.)]. Доступно по: http://www.consultant.ru/document/cons_doc_LAW_121895/. Ссылка активна на 12.05.2020.

[2] Приказ Минздрава России от 28.02.2019 № 103н «Об утверждении порядка и сроков разработки клинических рекомендаций, их пересмотра, типовой формы клинических рекомендаций и требований к их структуре, составу и научной обоснованности включаемой в клинические рекомендации информации» (Зарегистрировано в Минюсте России 08.05.2019 № 54588). [Order No. 103n Ministry Of Health Russia “Ob utverzhdenii poryadka i srokov razrabotki klinicheskikh rekomendatsiy, ikh peresmotra, tipovoy formy klinicheskikh rekomendatsiy i trebovaniy k ikh strukture, sostavu i nauchnoy obosnovannosti vklyuchayemoy v klinicheskiye rekomendatsii informatsii” (Zaregistrirovano v Minyuste Rossii 08.05.2019 No. 54588), dated 28.02.2019. (In Russ.)]. Доступно по: http://www.consultant.ru/document/cons_doc_LAW_324276/. Ссылка активна на 12.05.2020.

[3] Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID 19). Версия 6 (28.04.2020). [Vremennyye metodicheskiye rekomendatsii. Profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID 19). Version 6 (28.04.2020). (In Russ.)]. Доступно по: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf. Ссылка активна на 12.05.2020.

[4] Колбин А.С. Ранняя оценка эффективности лекарственных средств при лечении больных с COVID-19 // Инфекция и иммунитет. – 2020. – Т. 10. – № 2. – С. 277–286. [Kolbin AS. An early assessment of the efficacy of medicines in the treatment of patients with COVID-19. Russian Journal of Infection and Immunity. 2020;10(2):277-286. (In Russ.)]. https://doi.org/10.15789/2220-7619-AEA-1458.

[5] МосМедПрепараты.RU. Как не умереть от коронавируса: японский способ профилактики заражения [электронный ресурс]. [MosMedPreparaty.RU. Kak ne umeret’ ot koronavirusa: yaponskiy sposob profilaktiki zarazheniya [elektronnyy resurs]. (In Russ.)]. Доступно по: https://mosmedpreparaty.ru/news/20818. Ссылка активна на 12.05.2020.

[6] American Society of Hematology. COVID-19 and coagulopathy: frequently asked questions. From the ASH website. (Version 3.0; last reviewed June 23, 2020) Available from: https://www.hematology.org/covid-19/covid-19-and-coagulopathy. Ссылка активна на 23.06.2020.

[7] Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of Hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;ciaa237. https://doi.org/10.1093/cid/ciaa237.

[8] Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. https://doi.org/10.1136/bmj.m1849.

[9] Mahevas M, Tran VT, Roumie M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv. Cold Spring Harbor Laboratory Press; 2020. https://doi.org/10.1101/2020.04.10.20060699.

[10] Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493-2502. https://doi.org/10.1001/jama.2020.8630.

[11] Мирзаев К.Б., Сычев Д.А. Изменение позиции по применению гидроксихлорохина для профилактики и лечения COVID-19 [электронный ресурс]. [Mirzayev KB, Sychev DA. Izmeneniye pozitsii po primeneniyu gidroksikhlorokhina dlya profilaktiki i lecheniya COVID-19 [elektronnyy resurs]. (In Russ.)]. Доступно по: https://rmapo.ru/pharmacovid.html. Ссылка активна на 23.06.2020.

[12] Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020; NEJM doa2016638. https://doi.org/10.1056/NEJMoa2016638.

[13] Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019;32(2):176-186. https://doi.org/10.1097/QCO.0000000000000532.

[14] Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020;382(19):1787-1799. https://doi.org/10.1056/NEJMoa2001282.

[15] This national clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19. Available from: https://www.recoverytrial.net/.

[16] Goldman JD, Lye DC, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2015301.

[17] NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19 [cited April 29, 2020]. Available from: https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19.

RIGHTS & PERMISSIONS

Frolova E.V.